Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.9651
-0.0049 (-0.51%)
Apr 23, 2026, 10:08 AM EDT - Market open
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$52,571
Profits / Employee
-$1,361,417
Market Cap
23.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Aug 31, 2025 | 7 | 0 | - |
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Curis | 24 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| Barinthus Biotherapeutics | 14 |
| Serina Therapeutics | 13 |
| Skye Bioscience | 12 |
| Exicure | 8 |
LEXX News
- 1 hour ago - Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - Accesswire
- 1 hour ago - Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - TheNewswire
- 2 days ago - Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - Accesswire
- 8 days ago - Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - TheNewswire
- 16 days ago - Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - TheNewswire
- 22 days ago - Lexaria to Begin New Human Clinical Study in GLP-1 - TheNewswire
- 4 weeks ago - Lexaria's Robust Patent Portfolio Continues to Grow - Accesswire
- 4 weeks ago - Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - TheNewswire